Research Development Precision Oncology Molecular Tumour Board Based on the principle of getting the right treatment The VCCC’s monthly Molecular Tumour Board (MTB) to the right patient at the right time, this program is a highly-specialised multi-disciplinary meeting is developing the systems required to make cutting providing expert opinion and assessment of genomic edge genomic tests available to patients most likely test results. Presented as de-identified information, to benefit. this forum provides clinicians with a unique resource of expert opinion for their patients’ cases, as well as Guided by a steering group with representatives from recommendations for relevant clinical trials. every VCCC clinical partner this program is developing a system and framework for clinical decisions Interest in the MTB has grown significantly in the past regarding which patients are likely to benefit from year as the potential of precision oncology becomes genomic testing. more widely understood. A total of 436 clinicians and scientists attended the 11 MTB meetings in 2018, The system will also help ensure genomic testing is reviewing a total of 24 cases. conducted in a clinically useful time frame and include multi-disciplinary discussion of the implications of The Molecular Tumour Board (MTB) also plays the results of genomic tests for patients through an important educational role bridging genomic the VCCC’s expert Molecular Tumour Board. This assessments and the clinical workforce. information will be used to inform treatment recommendations based on genomic results, which Dates for Molecular Tumour Board meetings are may include enrolment in a clinical trial. available on the VCCC website. 45